Hesham Abboud

Multiple Sclerosis and Neuroimmunology Program, Case Western Reserve University, University Hospitals of Cleveland

[Hesham Abboud @AbboudHesham]

AIE clinical trials face numerous challenges while also providing many learning opportunities. Read this article on the clinical trial landscape in AIE.
#AIE
#autoimmuneencephalitis

https://t.co/N3NmMk0WkC

[Hesham Abboud @AbboudHesham]

First Cleveland Autoimmune Encephalitis Day. Speakers represented neuroimmunology, pediatric neurology, psychiatry, neuropsychology, and patient perspectives. We had a great turn out and highly engaged audience. Thanks to AEA, HESA, and Encephalitis411

[Hesham Abboud @AbboudHesham]

Join us in Cleveland on October 26 to hear the latest in autoimmune encephalitis. This event is for clinicians, patients, caregivers, and industry representatives

#encephalitis

https://t.co/kWrgjDX7B6

[Hesham Abboud @AbboudHesham]

Read about unilateral cortical autoimmune encephalitis; a novel anatomical subtype increasingly observed in the elderly.

Unilateral cortical autoimmune encephalitis: A case series and compari... https://t.co/3b2oulCmvC

[International Autoimmune Encephalitis Society @ae_society]

#Register for this #SpeakerSeries #Webinar with Hesham Abboud, MD, PhD of UH Cleveland Medical Center on #Paraneoplastic #autoimmune #Encephalitis
https://t.co/7sjbRiDutV
@cwru #CWRU @UHhospitals
@cwrusom
#neuroimmunology #Neurology #Psychiatry #neuroimmunology

[Hesham Abboud @AbboudHesham]

Neurological morbidity in patients with thyroid antibodies is rare but is not restricted to Hashimoto's encephalopathy. Read our latest findings from work lead by CWRU students and neurology residents:

https://t.co/NQB9ATaQKm

[Hesham Abboud @AbboudHesham]

Sharing the new UpToDate chapter on management of autoimmune encephalitis. We hope this chapter provides some guidance to clinicians managing autoimmune encephalitis until evidence-based therapies become available.

https://t.co/Faq4ESdKOJ

[Hesham Abboud @AbboudHesham]

A look into the pathology of seronegative autoimmune encephalitis from cases submitted to the the U.S National Prion Center. We hope this study improves our understanding of seronegative AE and guides future therapeutics.

https://t.co/40G5kzi6P4

[Hesham Abboud @AbboudHesham]

One step closer to evidence-based treatment for autoimmune encephalitis

#encephalitis
#uhproud

https://t.co/FRm0l3M9S1

[Neurology Journal @GreenJournal]

Announcing Neurology's new Assistant Editors, Hesham Abboud, MD, PhD, and Sarah E. Nelson, MD, MPH. Drs. Abboud & Nelson began their positions on April 1. Read more about them and join us in welcoming them to the Neurology team: https://t.co/suVRkOfCry

@AbboudHesham @senelson13

[Eoin Flanagan @EoinFlanagan14]

The criteria are a big step forward for MOGAD community ⁦⁦⁦⁦⁦⁦@TheMOGProject⁩ 👇Thanks to Brenda Banwell ⁦@FabienneBrilot⁩ ⁦@darshi_r⁩ ⁦@marignierro⁩ ⁦@antibodypad⁩ ⁦@jackie_palace⁩ & more for collaboration https://t.co/M8tWVf3MiM

[Hesham Abboud @AbboudHesham]

AddThis | Home How prevalent is iatrogenic CNS inflammation in the neuroimmunology clinic? Read our latest study on this topic https://t.co/zMaEeyOCLP

[Hesham Abboud @AbboudHesham]

Please join us on June 15th for the EUROIMMUN Neuroimmunology Summit to hear the latest in Autoimmune Neurology

[Hesham Abboud @AbboudHesham]

Happy to share the first and only prospective study of Parkinsonism in multiple sclerosis patients: https://t.co/GIBcVBJhB8

[Hesham Abboud @AbboudHesham]

May be we should be checking CD19 count and immunoglobulin levels to decide on vaccine timing in patients on B-cell depleting therapy. Read the details in this new study lead by our MS pharmacist Collin Jakubecz. #MultipleSclerosis #COVID19 https://t.co/6MElsP6YLH

[Hesham Abboud @AbboudHesham]

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments. happy to have worked with many great ECTRIMS membership on this led by @CarmenTur1 https://t.co/HTKmQNhKcY

[Hesham Abboud @AbboudHesham]

A French study of GFAP-IgG astrocytopathy. Monophasic course in 89% of patients. Four patients had reversible splenial lesions. Glial Fibrillary Acidic Protein Autoimmunity https://t.co/dTq9ZBizyW

[Hesham Abboud @AbboudHesham]

Our early experience with long-term outpatient management of AE survivors from the UH multidisciplinary AE Clinic. This study also provides external validation of the CASE score in a non-Asian population. https://t.co/msiZnQvTWK

[Hesham Abboud @AbboudHesham]

Studies+Find+Wide+Differences+in+How+MS+Therapies+Affect...+%3a+Neurology+Today https://t.co/xQAc5j4MJg

[Hesham Abboud @AbboudHesham]

Intrathecal baclofen pump for spasticity...#medicaltechoutlook via @MedTechOutlook https://t.co/6p4t8wu181